ClinicalTrials.Veeva

Menu

Exploration of Central Venous Catheter Protective Devices in the Pediatric Population: A Mixed Methods Study

The University of Texas System (UT) logo

The University of Texas System (UT)

Status

Completed

Conditions

Central Line

Treatments

Device: Gus gear protective wearable device

Study type

Observational

Funder types

Other

Identifiers

NCT05415449
STU-2022-0306

Details and patient eligibility

About

  1. to determine the feasibility of utilizing a wearable device
  2. to prospectively measure and evaluate parent and nurse satisfaction with the protective wearable device.

This is a sequential, convergent mixed methods study design in which qualitative interview data will be collected first followed by quantitative data.

Scheme and Outcomes: Identify eligible patients--Informed Consent--Provide education and two protective wearable device--Demographic data (electronic health record)--Interview parent on device--Every month complete 30-day satisfaction survey for a total of three data collection period-Discharge from study.

Nurse data collection scheme: Study participants hospitalized at time of enrollment in study or anytime during the study period. Nurse of patients using device will complete satisfaction survey.

Note: Vest is a Class I Exempt FDA-registered device.

Enrollment

30 patients

Sex

All

Ages

Under 12 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with CVCs ages 0 to 12 years of age
  • May currently utilizing or historically utilized the interventional wearable protective device
  • Caregiver or parent available
  • English and Spanish speaking subjects

Exclusion criteria

  • • Females with Tanner 2 breast or greater breast development. Justification: the wearable device will not fit properly to secure the CVC and may increase the risk of complications. If the patient does develop breast during the time of the study, then the patient will no longer wear the wrap and will go back to securing their device in the traditional way. Tanner 2 breast development will be evaluated in the screening process of patients.

    • Patients in critical care services such as neonates, trauma/ neurology intensive care unit, or cardiac intensive care unit. Justification: These patients are not mobile with their CVC and not the targeted population.

Trial design

30 participants in 1 patient group

No groups
Description:
Identify eligible patients--Informed Consent--Provide education and two protective wearable device--Demographic data (electronic health record)--Interview parent on device--Every month complete 30-day satisfaction survey for a total of three data collection period-Discharge from study. Nurse data collection scheme: Study participants hospitalized at time of enrollment in study or anytime during the study period. Nurse of patients using device will complete satisfaction survey.
Treatment:
Device: Gus gear protective wearable device

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Maria Leal, BSN, CPN

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems